Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients

Clin Gastroenterol Hepatol. 2022 Aug;20(8):1890-1891. doi: 10.1016/j.cgh.2021.09.030. Epub 2021 Sep 25.

Authors

Yen-Chun Liu¹, Wen-Juei Jeng¹, Chien-Hung Chen²

Affiliations

¹ Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City; College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
² Department of Gastroenterology and Hepatology, Kaohsiung Chang Gung Memorial Hospital, Taoyuan City; College of Medicine, Chang Gung University, Taoyuan City, Taiwan.

PMID: 34583016
DOI: 10.1016/j.cgh.2021.09.030

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents / adverse effects
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus / genetics
Hepatitis B, Chronic* / drug therapy
Humans
Nucleosides / adverse effects
Treatment Outcome

Substances

Antiviral Agents
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Nucleosides